Pfizer and Roivant launch autoimmune specialist Priovant
The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune diseases. The drug – called brepocitinib – is the centrepiece of the new biotech’s R&D pipeline and is already a pair of pivotal trials in […]